Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2026-04-14 @ 12:01 AM
Study NCT ID:
NCT02573467
Status:
COMPLETED
Last Update Posted:
2018-03-13
First Post:
2015-07-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Sponsor:
Novartis Pharmaceuticals
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module